FATIGUE AND MUSCLE FUNCTION IN PROSTATE CANCER SURVIVORS RECEIVING DIFFERENT TREATMENT REGIMENS

• Autor(a) principal: Chaves,Sandro Nobre
• Data de Publicação: 2019
• Outros Autores: Lima,Filipe Dinato de, Bottaro,Martim, Mota,Márcio Rabelo, Oliveira,Ricardo Jacó de
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Revista brasileira de medicina do esporte (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1517-86922019000600498
• topic: Prostatic neoplasms; Fatigue; Muscle strength; Physical fitness

ABSTRACT Introduction Prostate cancer is the most prevalent neoplastic disease in men. After diagnosis, different treatment regimens are proposed based on the stage of the cancer. These treatments affect physical and muscle function, quality of life, and prognosis differently. Objectives To assess fatigue, muscle strength, muscle thickness, and muscle quality in prostate cancer survivors undergoing androgen deprivation therapy (ADT). Methods Ten ADT patients, eight non-ADT patients and 18 healthy control subjects were enrolled in this study. Perceived fatigue was assessed through the 20-item Multidimensional Fatigue Inventory. Muscle thickness and quality (e.g., echo intensity) were assessed through B-mode ultrasound. Muscle strength and work capacity were assessed using an isokinetic dynamometer. The groups were compared with one-way ANOVA and Bonferroni adjustment. Results Muscle thickness, peak torque, and work capacity were lower in ADT than in the control group (CON) (p = 0.021; p = 0.005; p <0.001, respectively). ADT showed greater echo intensity than CON (p = 0.005) and N-ADT (p = 0.046). There were no differences between N-ADT and CON in terms of muscle thickness, peak torque, work capacity, and echo intensity (p >0.05). General fatigue was greater in both ADT (p = 0.030) and N-ADT (p = 0.047) compared to CON. Physical fatigue was greater in ADT than CON (p = 0.006). Conclusion ADT patients showed lower levels of muscle function and greater levels of perceived fatigue than healthy control subjects. It appears that muscle function remains lower in ADT patients, even several years after treatment initiation, although this does not apply to non-ADT patients. Level of evidence II; Diagnostic Studies - Investigating a Diagnostic Test.